Forms and compositions of a beta adrenergic agonist
AssigneeCuraSen Therapeutics, Inc.
InventorsWei Chen, Bing Xue, David Scott Carter
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to various forms and compositions useful as beta adrenergic agonists and uses of the same in the treatment of diseases associated with an adrenergic receptor. In one aspect, the disclosure provides a crystalline solid form of Compound 1: selected from Form A and Form B and salt forms thereof.
Claims21
A crystalline solid form of Compound 1:
- selected from Form A and Form B.
The crystalline solid form according to claim 0, wherein said compound is a crystalline solid substantially free of amorphous compound 1.
3-207. (canceled)
A salt form of compound 1:
- selected from:
- .
The method according to claim 0, wherein the β1-adrenergic receptor or β2-adrenergic receptor mediated disease or disorder is one or more selected from the group consisting of MCI (mild cognitive impairment), aMCI (amnestic MCI), Vascular Dementia, Mixed Dementia, FTD (fronto-temporal dementia;
- Pick’s disease), HD (Huntington disease), Rett Syndrome, PSP (progressive supranuclear palsy), CBD (corticobasal degeneration), SCA (spinocerebellar ataxia), MSA (Multiple system atrophy), SDS (Shy-Drager syndrome), olivopontocerebellar atrophy, TBI (traumatic brain injury), CTE (chronic traumatic encephalopathy), stroke, WKS (Wemicke-Korsakoff syndrome;
- alcoholic dementia & thiamine deficiency), normal pressure hydrocephalus, hypersomnia/narcolepsy, ASD (autistic spectrum disorders), FXS (fragile X syndrome), TSC (tuberous sclerosis complex), prion-related diseases (CJD etc.), depressive disorders, DLB (dementia with Lewy bodies), PD (Parkinson’s disease), PDD (PD dementia), ADHD (attention deficit hyperactivity disorder), Alzheimer’s disease (AD), early AD, and Down Syndrome (DS).
Dependencies are inferred from the claim text.